Саркоидное гранулематозное воспаление при проведении противовирусной терапии

Саркоидоз , саркоидное воспаление , гепатит С , интерферон-α

1. Hunninghake G.W., Costabel U., Ando M. et al. Statement on sarcoidosis. Sarcoidosis Vasc. Diffuse Lung Dis. 1999; 16 (2): 149-173.

2. Guglielmi V., Manghisi O.G., Pirrelli M., Caruso M.L. Granulomatous hepatitis in a hospital population in southern Italy. Pathologica 1994; 86 (3): 271-278.

3. Nagahama H., Higashi Y., Soejima M. et al. A case of sarcoidosis exacerbated after acute hepatitis C. Nihon Kokyuki Gakkai Zasshi 2002; 40 (7): 594-598.

4. Taga M., Abe T., Nishimura S. et al. A case of Sjogren's syndrome associated with chronic hepatitis C and sarcoidosis. Nihon Rinsho Meneki Gakkai Kaishi 2003; 26 (6): 336-340.

5. Bonnet F., Morlat P., Dubuc J. et al. Sarcoidosis-associated hepatitis C virus infection. Dig. Dis. Sci. 2002; 47 (4): 794-796.

6. Tsimpoukas F., Goritsas C., Papadopoulos N. et al. Sarcoidosis in untreated chronic hepatitis C virus infection. Scand. J. Gastroenterol. 2004; 39 (4): 401-403.

7. Kim T.H., Joo J.E. Spontaneous resolution of systemic sarcoidosis in a patient with chronic hepatitis C without interferon therapy. World J. Gastroenterol. 2006; 12 (1): 150-153.

8. Ohhata I., Ochi T., Kurebayashi S. et al. A case of subcutaneous sarcoid nodules induced by interferon-alpha. Nihon Kyobu Shikkan Gakkai Zasshi 1994; 32 (10): 996-1000.

9. Bobbio-Pallavicini E., Valsecchi C., Tacconi F. et al. Sarcoidosis following beta-interferon therapy for multiple myeloma. Sarcoidosis 1995; 12 (2): 140-142.

10. Teragawa H., Hondo T., Takahashi K. et al. Sarcoidosis after interferon therapy for chronic active hepatitis C. Intern. Med. 1996; 35 (1): 19-23.

11. Pietropaoli A., Modrak J., Utell M. Interferon-alpha therapy associated with the development of sarcoidosis. Chest 1999; 116 (2): 569-572.

12. Fiorani C., Sacchi S., Bonacorsi G., Cosenza M. Systemic sarcoidosis associated with interferon-a treatment for chronic myelogenous leukemia. Haematologica 2000; 85 (9): 1006-1007.

13. Goldberg H.J., Fiedler D., Webb A. et al. Sarcoidosis after treatment with interferon-alpha: A case series and review of the literature. Respir. Med. 2006; 100 (11): 2063-2068.

14. Hoffmann R.M., Jung M.C., Motz R. et al. Sarcoidosis associated with interferon-alpha therapy for chronic hepatitis C. J. Hepatol. 1998; 28 (6): 1058-1063.

15. Papaioannides D., Fotinou M., Korantzopoulos P. Sarcoidosis associated with interferon-? therapy for chronic hepatitis C. Med. Sci. Monit. 2004; 10 (1): 5-7.

16. Kosar F., Yurt S., Isik N. et al. Sarcoidosis associated with interferon-#a therapy for chronic hepatitis C. Eur. Respir. J. 2006; 28 (suppl. 50): ref. E3128.

17. Zissel G., Ernst M., Schlaak M. et al. Pharmacological modulation of the IFNgamma-induced accessory function of alveolar macrophages and peripheral blood monocytes. Inflam. Res. 1999; 48 (12): 662-668.

18. Vander Els N.J., Gerdes H. Sarcoidosis and IFN-alpha treatment. Chest 2000; 117 (1): 294.

19. Cacoub P., Sbai A., Frances C. et al. Systemic sarcoidosis during interferon-alpha therapy for chronic hepatitis C virus infection. Gastroenterol. Clin. Biol. 2000; 24 (3): 364-366.

20. Marzouk K., Saleh S., Kannass M., Sharma O.P. Interferon-induced granulomatous lung disease. Curr. Opin. Pulm. Med. 2004; 10 (5): 435-440.

21. Monsuez J.J., Carcelain G., Charniot J.C. et al. T cells subtypes in a patient with interferon-alpha induced sarcoidosis. Am. J. Med. Sci. 2009; 337 (1): 60-62.

22. Pohl J., Stremmel W., Kallinowski B. Pulmonal sarcoidosis: A rare side effect of interferon-alpha treatment for chronic hepatitis C infection. Z. Gastroenterol. 2000; 38 (12): 951-955.

23. Alfageme Michavila I., Merino Sanchez M., Perez Ronchel J. et al. Sarcoidosis following combined ribavirin and interferon therapy: a case report and review of the literature. Arch. Bronconeumol. 2004; 40 (1): 45-49.

24. Alazemi S., Campos M.A. Interferon-induced sarcoidosis. Int. J. Clin. Pract. 2006; 60 (2): 201-211.

25. Cogrel O., Doutre M.S., Marliere V. et al. Cutaneous sarcoidosis during interferon alfa and ribavirin treatment of hepatitis C virus infection: two cases. Br. J. Dermatol. 2002; 146 (2): 320-324.

26. Nawras A., Alsolaiman M.M., Mehboob S. et al. Systemic sarcoidosis presenting as a granulomatous tattoo reaction secondary to interferon-alpha treatment for chronic hepatitis C and review of the literature. Dig. Dis. Sci. 2002; 47 (7): 1627-1631.

27. Leclerc S., Myers R.P., Moussalli J. et al. Sarcoidosis and interferon therapy: report of five cases and review of the literature. Eur. J. Intern. Med. 2003; 14 (4): 237-243.

28. Rogers C.J., Romagosa R., Vincek V. Cutaneous sarcoidosis associated with pegylated interferon alfa and ribavirin therapy in a patient with chronic hepatitis C. J. Am. Acad. Dermatol. 2004; 50 (4): 649-650.

29. Yan K.K., Yanagawa H., Goto H. et al. A case of resectable lung adenocarcinoma associated with sarcoidosis. Med.Oncol. 1999; 16 (3): 216-220.

30. Hwang C.J., Gausas R.E. Sarcoid-like granulomatous orbital inflammation induced by interferon-alpha treatment. Ophthal. Plast. Reconstr. Surg. 2008; 24 (4): 311-313.

31. Menon Y., Cucurull E., Reisin E., Espinoza L.R. Interferon-Alpha-associated sarcoidosis responsive to infliximab therapy. Am. J. Med. Sci. 2004; 328 (3): 173-175.

32. Hunt J., Gordon F.D., Jenkins R.L. et al. Sarcoidosis with selective involvement of a second liver allograft: report of a case and review of the literature. Mod. Pathol. 1999; 12 (3): 325-328.

33. Gitlin N. Manifestation of sarcoidosis during interferon and ribavirin therapy for chronic hepatitis C: a report of two cases. Eur. J. Gastroenterol. Hepatol. 2002; 14 (8): 883-885.

34. Tahan V., Ozseker F., Guneylioglu D. et al. Sarcoidosis after use of interferon for chronic hepatitis C: report of a case and review of the literature. Dig. Dis. Sci. 2003; 48 (1): 69-73.

35. Perez-Alvarez R., Perez-Lopez R., Lombrana J.L. et al. Sarcoidosis in two patients with chronic hepatitis C treated with interferon, ribavirin and amantadine. J. Viral. Hepat. 2002; 9 (1): 75-79.